Benjamin K. Stoff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Benjamin K. Stoff has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Alisa M. Goldstein
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD
15 shared publications - Brittany C. Baikie
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
15 shared publications - Charles F. Lynch
Department of Epidemiology, University of Iowa , Iowa City, IA
15 shared publications - Elizabeth G. Berry
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA
15 shared publications - Emily Y. Chu
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
15 shared publications - Eric A. Engels
Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD
15 shared publications
Latest Publications
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Differentially expressed genes between adenomas and carcinomas.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Differentially expressed genes between adenomas and carcinomas.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
A. PCA plot of all transcriptomes including normal tissues. B. Upset plot of common differentially expressed genes between all histological category comparisons.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
A. PCA plot of all transcriptomes including normal tissues. B. Upset plot of common differentially expressed genes between all histological category comparisons.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Correlation between tumor purity as determined by pathology versus as calculated by PURPLE.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Correlation between tumor purity as determined by pathology versus as calculated by PURPLE.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Summary of non-malignant control tissues used for transcriptome comparisons.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Summary of non-malignant control tissues used for transcriptome comparisons.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Data from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Purpose:Sebaceous carcinoma is the third most common nonkeratinocyte skin cancer in the United States with 1,000 cases per year. The clinicopathologic features of sebaceous carcinoma and benign sebaceous neoplasms (adenomas, sebaceomas) can overlap, highlighting the need for molecular biomarkers to improve classification. This study describes the genomic and transcriptomic landscape of sebaceous neoplasms in order to understand tumor etiology and biomarkers relevant for diagnosis and treatment.Experimental Design:We performed whole-genome sequencing (WGS) and whole-transcriptome sequencing (WTS) of sebaceous neoplasms from six academic and two federal healthcare facilities in the United States diagnosed between January 1, 1999, and December 31, 2021.Results:We evaluated 98 sebaceous neoplasms: 64 tumors (32 adenomas, 2 sebaceomas, 5 atypical sebaceous neoplasms, 25 carcinomas) had sufficient material for WGS, 96 tumors (42 adenomas, 11 sebaceomas, 8 atypical sebaceous neoplasms, 35 carcinomas) had sufficient material for WTS, and 62 tumors (31 adenomas, 2 sebaceomas, 5 atypical sebaceous neoplasms, 24 carcinomas) had sufficient material for combined WGS and WTS. Overall, we found decreased cholesterol biosynthesis and increased TP53 mutations, copy number gains (chromosome 6, 8q, and/or 18), and tumor mutation burden-high (>10 mutations/MB) in carcinomas compared to adenomas. Although diminished compared to adenomas, most carcinomas still had higher cholesterol biosynthesis than nonmalignant skin. Multiomics profiling also supported a precancerous model of tumor evolution with sebaceomas and atypical sebaceous neoplasms being likely intermediate lesions.Conclusions:The study findings highlight key diagnostic biomarkers for sebaceous carcinoma and suggest that immunotherapy and modulation of cholesterol biosynthesis could be effective treatment strategies.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Purpose:Sebaceous carcinoma is the third most common nonkeratinocyte skin cancer in the United States with 1,000 cases per year. The clinicopathologic features of sebaceous carcinoma and benign sebaceous neoplasms (adenomas, sebaceomas) can overlap, highlighting the need for molecular biomarkers to improve classification. This study describes the genomic and transcriptomic landscape of sebaceous neoplasms in order to understand tumor etiology and biomarkers relevant for diagnosis and treatment.Experimental Design:We performed whole-genome sequencing (WGS) and whole-transcriptome sequencing (WTS) of sebaceous neoplasms from six academic and two federal healthcare facilities in the United States diagnosed between January 1, 1999, and December 31, 2021.Results:We evaluated 98 sebaceous neoplasms: 64 tumors (32 adenomas, 2 sebaceomas, 5 atypical sebaceous neoplasms, 25 carcinomas) had sufficient material for WGS, 96 tumors (42 adenomas, 11 sebaceomas, 8 atypical sebaceous neoplasms, 35 carcinomas) had sufficient material for WTS, and 62 tumors (31 adenomas, 2 sebaceomas, 5 atypical sebaceous neoplasms, 24 carcinomas) had sufficient material for combined WGS and WTS. Overall, we found decreased cholesterol biosynthesis and increased TP53 mutations, copy number gains (chromosome 6, 8q, and/or 18), and tumor mutation burden-high (>10 mutations/MB) in carcinomas compared to adenomas. Although diminished compared to adenomas, most carcinomas still had higher cholesterol biosynthesis than nonmalignant skin. Multiomics profiling also supported a precancerous model of tumor evolution with sebaceomas and atypical sebaceous neoplasms being likely intermediate lesions.Conclusions:The study findings highlight key diagnostic biomarkers for sebaceous carcinoma and suggest that immunotherapy and modulation of cholesterol biosynthesis could be effective treatment strategies.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Fraction of mutation signatures of mutants with a variant allele frequency less than 20% versus those with an allele frequency between 30% and 45%.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Fraction of mutation signatures of mutants with a variant allele frequency less than 20% versus those with an allele frequency between 30% and 45%.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Raw output of pathway prediction between adenomas and carcinomas from Ingenuity Pathway Analysis.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Raw output of pathway prediction between adenomas and carcinomas from Ingenuity Pathway Analysis.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Correlation between tumor purity as determined by pathology and PURPLE versus single base substitution signature abundance (counts) and relative fraction within a sample. A blue line with a light grey confidence interval represents the general linear model for the data points.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Correlation between tumor purity as determined by pathology and PURPLE versus single base substitution signature abundance (counts) and relative fraction within a sample. A blue line with a light grey confidence interval represents the general linear model for the data points.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Supplementary Table S2 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Supplementary Table S2 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Heatmaps of selected significantly altered pathways. A. Sirtuin signaling. B. Rho signaling C. TP53 signaling.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis
Heatmaps of selected significantly altered pathways. A. Sirtuin signaling. B. Rho signaling C. TP53 signaling.